Pere Gascón
Publicaciones destacadas
-
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppres
Autores:Referencia: ANNALS OF ONCOLOGY. -
Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma
Autores:Referencia: SUPPORTIVE CARE IN CANCER. -
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis
Autores:Referencia: EUROPEAN JOURNAL OF HAEMATOLOGY. -
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies
Autores:Referencia: ONCOLOGIST. -
Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer
Autores:Referencia: CANCER LETTERS.
Proyectos destacados
-
Inflammation and breast cancer: neuronal influence and pro-inflammatory neuropeptides in the tumoral progression through the modulation of the stem cell phenotype.
Financiador: INSTITUTE OF HEALTH CARLOS III. FISS PI12/01706Duración: 01/01/2013 -
Mechanisms of transactivation of ErbB family members in breast cancer: a role for tachykinins and the neoneurogenesis.
Financiador: INSTITUTE OF HEALTH CARLOS III. FISS PI080022Duración: 01/01/2009 -
Effect of integrins and neurokinins in cancer development”
Financiador: INSTITUTE OF HEALTH CARLOS III. FISS PI041353Duración: 01/01/2004